RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+10.4%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.97B
AUM Growth
+$233M
(+13%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
7.95%
Top 10 Holdings %
Top 10 Hldgs %
27.38%
Holding
158
New
16
Increased
48
Reduced
15
Closed
10
Top Buys
| 1 |
Medtronic
MDT
|
$35.5M |
| 2 |
UnitedHealth
UNH
|
$27.6M |
| 3 |
AET
Aetna Inc
AET
|
$25.5M |
| 4 |
Mersana Therapeutics
MRSN
|
$21.3M |
| 5 |
Thermo Fisher Scientific
TMO
|
$19.2M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$27.3M |
| 2 |
SHPG
Shire pic
SHPG
|
$24.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
$22.4M |
| 4 |
Amgen
AMGN
|
$16.1M |
| 5 |
PTHN
Patheon N.V.
PTHN
|
$10.5M |
Sector Composition
| 1 | Healthcare | 80.21% |
| 2 | Financials | 3.81% |
| 3 | Consumer Discretionary | 1.14% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Edwards Lifesciences
EW
$47.7B
| $22.5M | 1.13% |
570,003
+142,503
| +33% | +$5.62M |
|
|
AFAM
27
DELISTED
Almost Family Inc
AFAM
| $22.3M | 1.13% |
362,000
+137,000
| +61% | +$8.45M |
|
28
Gilead Sciences
GILD
$140B
| $22.2M | 1.12% |
313,400
+26,900
| +9% | +$1.9M |
|
29
Incyte
INCY
$17B
| $21.8M | 1.1% |
173,000
+4,000
| +2% | +$504K |
|
|
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
| $21.7M | 1.09% |
231,500
+47,000
| +25% | +$4.4M |
|
|
31
Mersana Therapeutics
MRSN
$34.8M
| $21.3M | 1.08% |
+61,116
| New | +$21.3M |
|
32
Neurocrine Biosciences
NBIX
$13.5B
| $19.3M | 0.97% |
419,000
+9,000
| +2% | +$414K |
|
33
Jazz Pharmaceuticals
JAZZ
$7.99B
| $19.2M | 0.97% |
123,700
| – | – |
|
|
34
Thermo Fisher Scientific
TMO
$183B
| $19.2M | 0.97% |
+110,000
| New | +$19.2M |
|
35
Hologic
HOLX
$14.7B
| $19.1M | 0.96% |
420,000
+80,000
| +24% | +$3.63M |
|
36
Danaher
DHR
$143B
| $19M | 0.96% |
253,800
+73,320
| +41% | +$5.49M |
|
|
WMGI
37
DELISTED
Wright Medical Group Inc
WMGI
| $18.4M | 0.93% |
670,000
| – | – |
|
38
Molina Healthcare
MOH
$9.6B
| $18.2M | 0.92% |
+263,500
| New | +$18.2M |
|
|
BCR
39
DELISTED
CR Bard Inc.
BCR
| $18.2M | 0.92% |
+57,500
| New | +$18.2M |
|
|
EPZM
40
DELISTED
Epizyme, Inc
EPZM
| $17.7M | 0.9% |
1,175,000
+605,000
| +106% | +$9.14M |
|
|
AMRN
41
Amarin Corp
AMRN
$311M
| $17.1M | 0.86% |
212,500
-37,560
| -15% | -$3.03M |
|
42
Galapagos
GLPG
$2.06B
| $16.9M | 0.86% |
221,500
+11,500
| +5% | +$880K |
|
43
Prothena Corp
PRTA
$452M
| $16.8M | 0.85% |
309,500
| – | – |
|
44
Vertex Pharmaceuticals
VRTX
$102B
| $16.6M | 0.84% |
129,000
+38,500
| +43% | +$4.96M |
|
45
Puma Biotechnology
PBYI
$258M
| $16.3M | 0.82% |
186,000
+91,500
| +97% | +$8M |
|
46
Willis Towers Watson
WTW
$31.9B
| $16M | 0.81% |
110,000
| – | – |
|
47
Exact Sciences
EXAS
$9.33B
| $15.5M | 0.78% |
437,500
+100,000
| +30% | +$3.54M |
|
|
PRTK
48
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $14.5M | 0.73% |
600,000
+74,500
| +14% | +$1.8M |
|
49
Biogen
BIIB
$20.5B
| $14.4M | 0.73% |
53,000
+5,000
| +10% | +$1.36M |
|
|
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
| $14.4M | 0.73% |
175,000
+35,000
| +25% | +$2.88M |
|